含活水痘病毒疫苗一剂或两剂:健康儿童生命第二年接种后六年的效力、免疫应答持久性与安全性
这项III B期随访研究纳入来自十个欧洲国家的5289名12至22月龄健康儿童,随机分别接种两剂MMRV、一剂MMR加一剂水痘疫苗或两剂MMR对照,评估接种后六年针对全部水痘及中重度水痘的效力。两剂MMRV对全部水痘效力为95.0%(95%CI:93.6-96.2),对中重度水痘为99.0%(95%CI:97.7-99.6);一剂水痘疫苗分别为67.0%(95%CI:61.8-71.4)和90.3%(95%CI:86.9-92.8)。
要点
- 两剂MMRV六年后对全部水痘效力95.0%,对中重度水痘效力99.0%。
- 一剂水痘疫苗六年后对全部水痘效力67.0%,对中重度水痘效力90.3%。
- 共确认4例带状疱疹,MMR+V组2例、MMR组2例,均为轻症。
核心结论
- 两剂MMRV疫苗和一剂水痘疫苗在接种后六年内仍保持效力。
研究设计与样本
- III B期随访研究为初始多中心研究(NCT00226499)的延续,评估接种后十年效力,本报告呈现接种后六年效力结果。
- 健康儿童来自十个欧洲国家,年龄12至22月龄,按3:3:1随机分为两剂MMRV组、一剂MMR加一剂水痘疫苗组和两剂MMR对照组,间隔42天接种。
- 效力评估从第二剂后六周至六年,针对全部水痘及中重度水痘(经病毒DNA检测或流行病学关联确认),并计算95%CI。
- 水痘严重程度采用改良Vázquez量表(轻度≤7;中度严重8-15;重度≥16),同时记录带状疱疹病例。
- 效力队列共5289名儿童:MMRV组2279名(平均年龄14.2月,标准差2.5);MMR+V组2266名(平均年龄14.2月,标准差2.4);MMR组744名(平均年龄14.2月,标准差2.5)。
主要发现
- 共确认815例水痘病例。
- 两剂MMRV对全部水痘效力为95.0%(95%CI:93.6-96.2),对中重度水痘效力为99.0%(95%CI:97.7-99.6)。
- 一剂水痘疫苗对全部水痘效力为67.0%(95%CI:61.8-71.4),对中重度水痘效力为90.3%(95%CI:86.9-92.8)。
- 共确认4例带状疱疹(MMR+V组2例,MMR组2例),均为轻症,其中3例检测为野生型病毒阳性。
关键数值与推荐
- 两剂MMRV对全部水痘效力95.0%(95%CI:93.6-96.2),对中重度水痘效力99.0%(95%CI:97.7-99.6)。
- 一剂水痘疫苗对全部水痘效力67.0%(95%CI:61.8-71.4),对中重度水痘效力90.3%(95%CI:86.9-92.8)。
- 改良Vázquez量表分级:轻度≤7;中度严重8-15;重度≥16。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This phase III B follow-up of an initial multicenter study (NCT00226499) will evaluate the ten-year efficacy of two doses of the combined measles-mumps-rubella-varicella vaccine (MMRV) and one dose of the live attenuated varicella vaccine (V) versus a measles-mumps-rubella control group (MMR) for the prevention of clinical varicella disease. Here we present efficacy results for six years post-vaccination. METHODS: In phase A of the study, healthy children aged 12-22 months from ten European countries were randomized (3:3:1) and received either two doses of MMRV, or one dose of combined MMR and one dose of monovalent varicella vaccine (MMR+V), or two doses of the MMR vaccine (control), 42 days apart. Vaccine efficacy against all and against moderate or severe varicella (confirmed by detection of viral DNA or epidemiological link) was assessed from six weeks up to six years post-dose 2 for the MMRV and MMR+V groups, and was calculated with 95% confidence intervals (CI). The severity of varicella was calculated using the modified Vázquez scale (mild ≤ 7; moderately severe = 8-15; severe ≥ 16). Herpes zoster cases were also recorded. RESULTS: 5289 children (MMRV = 2279, mean age = 14.2, standard deviation [SD] = 2.5; MMR+V = 2266, mean age = 14.2, SD = 2.4; MMR = 744, mean age = 14.2, SD = 2.5 months) were included in the efficacy cohort. 815 varicella cases were confirmed. Efficacy of two doses of MMRV against all and against moderate or severe varicella was 95.0% (95% CI: 93.6-96.2) and 99.0% (95% CI: 97.7-99.6), respectively. Efficacy of one dose of varicella vaccine against all and against moderate or severe varicella was 67.0% (95% CI: 61.8-71.4) and 90.3% (95% CI: 86.9-92.8), respectively. There were four confirmed herpes zoster cases (MMR+V = 2, MMR = 2), all were mild and three tested positive for the wild-type virus. CONCLUSIONS: Two doses of the MMRV vaccine and one dose of the varicella vaccine remain efficacious through six years post-vaccination.
引用
- Henry O, Brzostek J, Czajka H, et al. One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life. Vaccine. 2017. PMID: 29224964. doi:10.1016/j.vaccine.2017.11.081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。